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Abstract
This chapter examines key concepts with respect to cancer gene therapy and the cur‐
rent issues with respect to non-viral delivery. The biological and molecular barriers
that need to be overcome before effective non-viral delivery systems can be appropri‐
ately designed for oncology applications are highlighted and ways to overcome these
are discussed. Strategies developed to evade the immune response are also described
and targeted gene delivery is examined with the most effective strategies highlighted.
Finally, this chapter proposes a new way forward based on a growing body of evi‐
dence that supports a multifunctional delivery approach involving the creation of vec‐
tors, with a unique molecular architecture designed using a bottom-up approach.
Keywords: Cancer gene therapy, Multifunctional delivery systems, Non-viral gene
delivery, Bio-inspired vectors, Tumour-targeted delivery
1. Introduction
Progress in the treatment of cancer in recent times has been unprecedented as cancer survival
in the UK has doubled in the last 40 years, with 50% of adult cancer patients diagnosed in 2010–
2011 in England and Wales predicted to survive 10 years or more [1]. Improvements in cancer
screening techniques have led to improved prognosis through early detection, with breast
cancer screening estimated to prevent up to 1,300 deaths per year; women who are diagnosed
with the earliest stage of breast cancer have a 90% 5-year survival rate [2]. Likewise, if
diagnosed early, prostate cancer responds well to treatments such as hormone therapy, with
65–90% of men diagnosed in stage 1 or 2 likely to live at least 10 years post diagnosis [3]. Despite
improvements in screening and early detection methods, conventional treatment options are
not always effective. Mainstay cancer treatment options including radiotherapy, chemother‐
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apy, and surgery are extremely arduous on patients, and often have only moderate success.
Existing anticancer drugs are generally cytotoxic, but lack specificity for the target tumour,
which results in severe side effects. Not only do these traditional therapies cause damage to
healthy cells, they are rarely effective against all transformed cells, and sometimes lack potency
entirely. Failure of treatment can result in disease recurrence, often in a more aggressive form,
with chemo- and radio-resistant aggressive malignancies ensuing. Resistance to conventional
therapy causes treatment failure in over 90% of patients with advanced metastatic cancer [4].
Gene therapy is an exciting research area that involves the delivery of genetic material into
cells to alter their function. Diseases that arise consequential of anomalous DNA (e.g., cystic
fibrosis [5, 6]) are appropriate for gene therapy intervention; as cancer’s origins lie in DNA
damage, this group of diseases is also particularly suitable for gene-based therapeutics [7]. The
strategy of gene therapy is generally to replace or repair faulty genes by the transfer and
insertion of corrective or therapeutic genes [8]. Alternatively, the strategy of gene therapy can
be the supraphysiological expression of cytotoxic proteins, or the expression of proteins to
affect metabolism of prodrugs, for direct or indirect cytocidal effects, respectively [9]. Silencing
of problematic genes is a nascent and very popular strategy that uses RNAi therapeutics to
inhibit the expression of certain undesirable genes at the post-transcriptional level [10]. Some
of the most common strategies of cancer gene therapy include suicide gene therapy, tumour
suppressor gene therapy, antiangiogenic therapy, and cancer immunotherapy [11].
1.1. Tumour suppressor gene therapy
Mutation of tumour suppressor genes, such as p53, has been highlighted as a mechanism of
proliferation and resistance in some cancers. Functional p53 interacts with other cellular
pathways including the death-receptor pathways and caspases, as well as inhibiting anti-
apoptotic mediators, such as the BCL family, leading to the suppression of tumour growth [12].
For this reason, the delivery of transgenes that encode tumour suppressor genes, including
genes encoding p53, IL-2, EGFR, and E1A, has received considerable attention. Promising
results have been obtained, with Senzer et al. reporting the systemic administration of targeted
liposomal nanoparticles with an anti-transferrin receptor targeting moiety (TfR); they deliv‐
ered the p53 tumour suppressor gene in complexes known as SGT-53 for advanced solid
tumours in a phase I clinical trial [13]. SGT-53 was administered to patients with a range of
advanced cancer types, including cervical cancer, thyroid cancer, and colorectal cancer.
Median survival was 340 days and 7 of the 11 patients treated exhibited stable disease at 6-
week assessment, with one patient reclassified from inoperable to operable due to significant
tumour necrosis. The authors also demonstrated the tumour targeting ability of SGT-53 with
biopsies of tumour tissue and normal tissue; normal tissue showing negligible exogenous p53
levels. However, the main aim of the study was to assess safety and further studies would be
required to fully assess therapeutic effects.
1.2. Suicide gene therapy
Suicide gene therapy, also known as gene-directed enzyme-producing therapy (GDEPT),
involves the administration of an enzyme-encoding transgene to the tissue, with a separate
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administration of a relatively innocuous prodrug. Transgene expression produces the enzyme
within cancerous cells and subsequently the prodrug is converted to its toxic form by this
enzyme [14]. GDEPT strategies include cytosine deaminase/F-fluorocytosine (CD/5-FC),
where the CD transgene metabolises 5-FC to 5-Fluorouracil (5-FU); herpes simplex virus
thymidine kinase/ganciclovir (HSVtk/GCV) where HSVtk coverts GCV to its cytotoxic
triphosphate derivative; and E. coli nitroreductase/CB1954 (NTR/CB) where NTR activates the
prodrug CB1954 resulting in toxicity to tumour cells [15]. Multiple GDEPT systems have made
it to clinical trials and Sangro et al. reported on a recent phase 1 clinical trial of HSVtk/GCV in
the treatment of advanced hepatocellular carcinoma. Intra-tumoural injection of the TK gene
in a replication deficient adenovirus vector (Ad-TK) was followed with systemic administra‐
tion of GCV in 10 patients [16]. Although the main aims of the trial were to assess feasibility
and safety of treatment, anti-tumour effects were also assessed. Stabilisation of tumour was
observed in 60% of patients, with two patients who received the high dose treatment showing
tumour necrosis and one patient surviving for 26 months. Such therapies, which may be used
in addition to radiotherapy, have the advantage of being activated only in the cancerous cells
due to direct intra-tumoural delivery, reducing toxic side-effects to normal cells. A ‘bystander
effect’ where neighbouring cells receive the toxic treatment through gap junctions has also
been observed, which could be beneficial for therapy as reduced amounts of treatment are
needed for the same therapeutic effect; conversely, this bystander effect may limit the potential
of the therapy if neighbouring healthy cells receive the toxic treatment. However, problems in
vector development still need to be overcome before these treatments are to be successful [17].
Despite progression to clinical trials, no GDEPT therapy has made it to the market and the use
of such treatment strategies may be limited to locally available tumour sites due to the need
for intra-tumoural injection.
1.3. Anti-angiogenic therapy
In contrast to suicide gene therapy and tumour suppressor therapy, which are quite specific
in focus, targeting angiogenesis may attack the root of the greater tumour establishment. There
are various ‘classical’ protein-based angiogenesis inhibitors, including receptor tyrosine kinase
inhibitors, which block the activity of vascular endothelial growth factor (VEGF), and mono‐
clonal antibodies against VEGF-A such as bevacizumab (Avastin®). However, as angiogenesis
is required for normal function in the body, such as wound healing, complete blockade of
angiogenesis is not desirable. In addition, it may seem that rather than kill tumours, inhibitor
therapy may merely retard further tumour growth. Moreover, the existence of various
resistance mechanisms to angiogenic inhibitors, including alternative signalling pathways
poses major drawbacks to such therapy. Alternatively, a gene therapy approach targeting the
genes behind the pro-angiogenic factors may be more suitable [18, 19]. Doan et al. described
a gene silencing approach that halts the effects of the pro-angiogenic factors VEGF and kinesin
spindle protein (KSP), which play a critical role in cellular proliferation [20]. Hep3B hepato‐
cellular carcinoma cells were treated with a cocktail of anti-VEGF and anti-KSP siRNAs, and
a significant reduction in both VEGF and KSP expression was observed; in vitro, this mani‐
fested reduced proliferation of the cells, assessed by WST-1 assay and clonogenic survival
assay. The results demonstrate the potential for anti-angiogenic gene therapy, but translation
to in vivo studies is required to establish this further.
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1.4. Cancer immunotherapy
Cancer immunotherapy is the process of harnessing the immune system to attack cancer cells.
Cancer cells present antigens, known as tumour-associated antigens (TAAs) or tumour-
specific antigens (TSAs) on their surface; recognition of these antigens by immune cells has
been exploited in the development of cancer DNA vaccines. Cancer vaccines may be prophy‐
lactic or therapeutic in their design, which would generate an active immune response
specifically to tumours while also providing memory cells to control future recurrence [21].
DNA encoding the genes for TAAs is delivered to cancer cells that subsequently express the
transgenic TAA, eliciting an immune response against the tumour cells and many cancer DNA
vaccines are being assessed in clinical trials [22]. Chudley et al. reported on a phase I/II clinical
trial of a DNA vaccine encoding a domain (DOM) from fragment C of a tetanus toxin linked
to an HLA-A2-binding epitope from prostate-specific membrane antigen (PSMA) in patients
with prostate cancer [23]. Following intramuscular administration of the DNA vaccine to 30
patients, 29 had a measurable CD4+ T-cell response and PSMA-specific CD8+ T cells were
detected in 16/30 patients. As a result, PSA doubling time increased significantly from 11.97
months pre-treatment to 16.82 months denoting slower progression of the disease. Staff et al.
reported on a phase I clinical trial in patients with colorectal cancer with a DNA vaccine [24].
The plasmid vaccine was administered by Biojector® and encoded human carcinoembryonic
antigen (CEA), which is known to be over expressed by a large number of epithelial neoplasias,
including colorectal cancer. No serious adverse effects were observed with the vaccine and of
the 10 patients, 8 showed no evidence of disease at follow-up. However, despite the promising
trial results and 4 DNA vaccines licensed for use in animals including Oncept® for Canine
Melanoma [25], no product has made it to the market in humans. Many trials use direct
injection of the vaccines to tumours and efficiency may be enhanced if delivery vectors were
to be used, which could maximise transduction.
To date, cancer has been the most common disease focus for gene therapy, with 64% of all
ongoing gene therapy clinical trials targeting a malignancy [26]. However, the progress of gene
therapy beyond clinical trials has been disappointing, with only three products currently
having made it to the market, namely, Gendicine®, Oncorine®, and Glybera®. Gendicine®
and Oncorine®, which deliver p53 tumour suppressor genes for the treatment of head and
neck cancer, are licenced in China; while Glybera®, used for the treatment of severe lipoprotein
lipase deficiency, is the only gene therapy product licensed in Europe [27]. Despite the many
promising therapeutic strategies for gene therapy, the common limiting factor has been the
lack of a suitable delivery vehicle that has the ability to specifically target tumour cells, whilst
being non-immunogenic and non-toxic. Consequently, a vast amount of research has therefore
focused on delivery systems for gene therapy. In order for the potential of gene therapy to be
realised, the focus needs to be on the design of an appropriate delivery vehicle that will meet
all the demands in terms of functionality and satisfaction of regulatory bodies.
2. The biological barriers to gene delivery
The safest way to deliver gene therapy is by direct administration of the therapeutic to the
target site. However, this is extremely inefficient, unreliable, and feasible only in tumours in
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superficial sites. Generally, gene therapy approaches are delivered via the intravenous route;
as nucleic acids are susceptible to degradation by nucleases and rapid clearance in systemic
circulation [28], a vector is required to package, protect, and transport the genetic material to
its site of action.
Viral vectors, derived from naturally evolved viruses capable of transferring their genetic
material into host cells, remain the most efficient gene delivery agents [29]. However, difficulty
in large scale production, limitation in size of DNA that can be carried, and concerns about
mutagenesis, toxicity, and immunogenicity have hindered the progression of viral vectors [30,
31]. As a result, much research has focused on the design of non-viral vectors, which have the
potential to circumvent the problems associated with viral vectors [32]. Non-viral gene
delivery encompasses a wide variety of delivery systems including cationic polymers,
liposomes, proteins, and peptides that have the ability to package nucleic acids and deliver
them into cells [33]. However, transfection efficiency of non-viral vectors remains significantly
lower than viral vectors [34], and many factors are to be considered and hurdles overcome
when designing an efficient non-viral delivery system. Successful gene therapy relies largely
on the development of an efficient vector that can overcome the various extracellular and
intracellular barriers to deliver the genetic material to its target site [35].
2.1. Extracellular barriers
Although delivery vectors have the ability to protect the DNA from endonuclease attack, the
vectors themselves may also be susceptible to recognition and clearance. In the systemic
circulation, vectors may be rapidly cleared from circulation by the reticulo-endothelial system
(RES), also known as the mononuclear phagocyte system (MPS) [36]. Many non-viral delivery
vectors are cationic in nature, a desirable characteristic for condensing DNA and promoting
cellular uptake. However, this cationic nature can be problematic for systemic administration
due to interaction with blood components, such as serum proteins, which may result in
opsonisation. Consequently, large aggregates are formed that cannot traverse cell membranes
and may become lodged in microvascular networks or accumulate in MPS organs such as the
liver or spleen [37]. Further to this, cationic systems may interact with cell membranes
indiscriminately, affecting normal cells as well as cancerous cells, and strong cationic charges
can induce damage of cellular membranes and apoptosis [38]. Thus, a balance must be reached
in the design of a delivery vector such that the nucleic acid/vector complex has cationicity of
appropriate magnitude, so as to permit proper association with target cells whilst preventing
aggregation.
The circulation of gene therapy delivery systems is often cut short due to rapid hepatic
metabolism and clearance, and often this clearance occurs before the particles can reach their
target site to deliver the therapeutic. The use of ‘stealth particles’, such as those that contain
polyethylene glycol (PEG), has been shown to increase the circulation time of various delivery
systems by shielding the charge of the particles, reducing binding with serum proteins and
aggregation, whilst evading the immune system [39]. Various strategies in evading this
clearance have been employed, which will be discussed in a later section. However, if the vector
can avoid clearance, extravasation from blood circulation needs to occur in order to reach the
tumour cells, which can be hindered by the chaotic blood supply, poor permeability, and high
interstitial pressure within the tumour [40].
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2.2. Intracellular barriers
Surviving the systemic circulation and reaching the target cell is not the only hurdle faced by
non-viral gene delivery systems. The nature of conventional gene therapy requires the genetic
material to be transcribed by the cell, which requires delivery to the nucleus (or in the case of
siRNA technology, delivery to the cytoplasm). A number of intracellular barriers exist that
may impede this delivery include traversing the cell membrane, escape from the endosome,
and release of the nucleic acid payload into the cytoplasm, followed by active transport to the
nucleus with subsequent nuclear import.
2.2.1. Cell membrane/internalisation
Cell membranes are lipophilic anionic structures that are generally impermeable to large
macromolecular anionic nucleic acids [32]. Non-viral gene delivery systems aim to complex
nucleic acid cargo, thereby masking their native negative charge, to give an overall net cationic
complex capable of interaction with cell membranes. Not only does this allow for electrostatic
interactions between the vector and the membrane, it also condenses the DNA to a size suitable
for cellular uptake (≤200 nm diameter). Various pathways of cellular uptake exist that are size
dependent. For example, the cell penetrating peptide TAT, derived from the human immu‐
nodeficiency-1 virus (HIV-1) [41], enters cells via different routes depending on the size of the
cargo. Larger cargoes of proteins or quantum dots that exceed the 500 Daltons restriction limit
are internalised with TAT via the caveolae or macropinocytosis routes, and smaller cargoes
such as peptides less than 30–40 amino acids via the clathrin route [42]. Further to this, the
internalisation route may also depend on other factors such as cell type, receptors present on
the cell, temperature, incubation time, concentration of the vector, and properties of the vector
including cargo and linkage type [7, 43]. Different internalisation pathways also have an effect
on the fate of the vector once inside the cell. As a result, much research has centred around
elucidating the mechanisms involved in cellular uptake in order to improve the efficiency of
gene therapy [44]. Endocytosis (clathrin-mediated, caveolae-mediated, or macropinocytosis)
is thought to be the main uptake pathway for most gene delivery.
2.2.2. Clathrin-Mediated Endocytosis (CME)
CME is the most well-defined route of endocytosis and involves the internalisation of cargo
via receptors on the cell membrane, such as proteoglycans, into vesicles known as clathrin
coated pits, which are about 100–150 nm in diameter. These pits are transported via microtu‐
bules of the cell cytoskeleton deeper into the cell, where they form endosomes (acidic,
degradative compartments that transport material back to the membrane for recycling, or to
lysosomes for degradation). The term ‘receptor-mediated endocytosis’ is often used to describe
CME, however, endocytosis via receptors does not exclusively occur via CME [45]. The
addition of ligands, such as transferrin, to delivery systems has allowed for targeting to cancer
cells overexpressing the transferrin receptor that binds to the ligand and facilitates internali‐
sation via CME [46].
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2.2.3. Caveolae-Mediated Endocytosis (CvME)
CvME is initiated by flask-shaped invaginations known as caveolae that have lipid-raft
formations involving cholesterol and sphingolipids, which are around 50–200 nm in diameter.
Internalisation occurs in an actin-dependent manner, forming a type of endosome known as
a caveosome. Caveosomes are not as acidic or destructive as CME endosomes, but can still
ultimately merge with the lysosomal machinery [47]. It has been observed that many com‐
monly used cancer cells lines (e.g., PC-3 prostate cancer cells) lack the ability to form caveolae
that may have significance for delivery systems relying on this route for internalisation [48].
Furthermore, it has been observed that caveolae may be upregulated in some cancer cells
providing a possible target for delivery systems. Nguyen et al. reported that a polysorbitol-
mediated transporter (PSMT) was used to deliver plasmid DNA encoding the p53 tumour
suppressor gene into human cervical cancer (HeLa) cells and normal human diploid fibroblast
(HDF) cells. PSMT entered cancer cells selectively via CvME with transgene expression
resulting in cellular damage and apoptosis [49].
2.2.4. Macropinocytosis
Macropinocytosis involves the uptake of large amounts of fluid-phase materials. It occurs via
an actin-driven mechanism that causes ruffling of the cell membrane to form protrusions that
engulf the extracellular material into macropinosomes, which eventually merge with the
endosomal pathway [50]. Anaka et al. reported that macropinocytosis was the main cellular
uptake pathway of the peptide STR-CH2R4H2C when complexed with plasmid DNA and
delivered to COS7 kidney fibroblast cells, attributing the position of arginine residues exposed
on the surface of the complexes as the reason for this internalisation route [51].
2.2.5. Direct internalisation
Cationic vectors, especially those rich in arginine, have been observed to enter cells via non-
endocytic routes through direct internalisation triggered by non-specific electrostatic interac‐
tions [52]. This form of internalisation is a more attractive route for non-viral gene delivery, as
direct delivery into the cytoplasm avoids the endosome. In the case of arginine-rich cell
penetrating peptides, an initial electrostatic interaction with the cell membrane is followed by
formation of a peptide-cargo-phospholipid complex with the positively charged guanidium
group of arginine bound to the phosphate groups of the phosphatidylcholine (PC) and/or
sphingomyelin (SM) of the outer leaflet of the cell membrane. A ‘capacitor’ is then formed
between the cationic arginine residues and the anionic phosphatidylserine creating an electric
field strong enough to form a reversible pore, which allows the CPP-cargo to pass through the
membrane [53]. Arginine-rich peptides, such as octa-arginine (R8), have therefore been utilised
for gene delivery due their strong cell penetrating ability. However, little is known about this
entry route, and evidence suggests that vectors can enter cells via multiple mechanisms [54].
Understanding the various routes through which vectors can enter cells can aid the gene
therapist in the design of vectors; ensuring appropriate size and charge, for example, can allow
for targeted internalisation via a specific mechanism.
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2.3. Endosomal entrapment
Following endocytosis, vectors may be trapped in the endosomal pathway. Endosomal
entrapment poses a major limiting step to efficient gene therapy. The endosomal compartment
provides cells with a way of regulating what enters and leaves the cell and material within the
endosome can be either recycled to the cell membrane or progressed to lysosomes. It is essential
that therapeutics escape the endosome in order to avoid degradation of the nucleic acid
payload [55]. Endosomal escape can be achieved by different mechanisms and typically non-
viral delivery systems are designed to facilitate this. The ‘proton sponge’ effect is exploited by
polymers that contain amine groups such as polyethylenimine (PEI) or by histidine-rich
peptides, which have been used in many delivery systems for gene therapy [56]. Fusogenic
peptides evoke membrane destabilisation by interacting with anionic lipids in the endosomal
membrane, thereby disrupting the membrane, allowing release of the endosomal contents [57].
INF-7 peptide is an example of a synthetic fusogenic peptide derived from influenza virus
hemagglutinin protein, which enhances endosomal escape. Oliviera et al. report that the
addition of INF-7 peptide to Lipofectamine for delivery of anti-kRas siRNA resulted in 3.5-
fold improved gene silencing effect and subsequent reduction in kRas protein expression in
C26 murine colon carcinoma cells in vitro when compared to Lipofectamine/siRNA complexes
alone [58].
2.4. Intracellular trafficking
Following endosomal escape, the vector and its cargo must be delivered to the correct cellular
compartment, i.e.,  DNA delivered to the nucleus, or siRNA assembly into RNA-induced
silencing complexes (RISC) in the cytoplasm [59, 60]. However, this is not without its challeng‐
es due to the restricted movement of macromolecules in the cell, slowing the mobility of vectors
towards the nucleus [61], while endonucleases may degrade any naked nucleic acid [62]. The
vector is therefore required to protect and transport the nucleic acid through the cytoplasm in
order to reach its target organelle. Movement in the cytoplasm is restricted due to overcrowd‐
ing of organelles, the cell cytoskeleton and high protein concentrations, which collectively result
in a major impediment to non-viral delivery of even relatively small cargoes [63]. A network of
microtubules and associated motor proteins (dyneins and kinesins) are responsible for the
maintenance of correct organelle location [64] and intracellular transport of vesicles, lyso‐
somes, and endosomes [65]. If non-viral gene delivery vectors could utilise the microtubule
network within the cell, it would serve as a direct route to the nucleus and transfection efficiencies
may be greatly improved. Toledo et al. presented a recombinant fusion protein based on the
dynein light chain LC8 that facilitated plasmid DNA uptake into HeLa cells and transported
DNA via microtubules to the nucleus for GFP transgene expression [66].
2.5. Nuclear import
In the case of DNA gene therapy, once the vector reaches the nucleus, it must gain entry and
deliver its genetic payload in order for the gene to be transcribed and elicit its effect. The
nucleus is protected by a bilayer known as the nuclear envelope, and entry into the nucleus
through the nuclear envelope is tightly controlled by the nuclear pore complex (NPC) [67].
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The NPC only allows the passive entry of molecules that do not exceed 10 nm in diameter,
which limits the entry of DNA; active traversing of the nuclear envelope is hence required.
The NPC therefore poses the last major hurdle to gene therapy and is a huge rate-limiting step
in transfection efficiency. The addition of short amino acid sequences known as nuclear
localisation signals (NLS) to vectors has been useful in trafficking and facilitating nuclear entry
[68]. The nuclear localisation signal from the simian virus 40 (SV40), large tumour antigen has
been used to enhance transfection efficiency in many delivery systems. Wang et al. demon‐
strated that the addition of SV40 NLS to R8 resulted in a transfection efficiency of up to 80%
as effective as jetPEITM (transfection reagent) with no cytotoxic effects in HeLa cells [69].
Understanding the various barriers to gene delivery allows the rational design of delivery
systems that can overcome these hurdles. The ideal non-viral gene delivery vector is a multi-
functional system with the ability to condense DNA effectively, overcome the various intra-
and extracellular barriers and must also be non-toxic and non-immunogenic. Furthermore,
vectors can be designed specifically to exploit the characteristics of cancer cells and tumours,
including the enhanced permeability and retention (EPR) effect associated with tumour
vasculature; where gene therapy delivery systems exploit the permeability of the tumour
vasculature to localise and accumulate in the tumour through passive diffusion [70]. Other
factors, including tumour microenvironment, and the aberrant expression of certain enzymes
and proteins commonly associated with cancer cells may also be targeted or exploited. Figure
1 represents how a multi-functional non-viral gene delivery system may be composed.
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Figure 1. Schematic of a multi-functionalised vector for therapeutic transgene delivery.
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Anionic plasmid DNA cargo is condensed using a cationic material such as poly-L-lysine or
protamine. Vectors are functionalised with adjuncts to aid in evasion of the various barriers
that are posed to gene therapy strategies, as highlighted above. The various functional groups
will be discussed below.
3. Evading the immune response
When gene delivery systems are administered systemically they are usually cleared rapidly
from circulation, mainly by Kupffer cells in the liver and macrophages in the spleen. This is a
form of defence by the host designed to recognise and clear potentially harmful invaders from
the system as quickly as possible, and involves a two-step process initiated by opsonisation
with subsequent phagocytosis [71]. Opsonisation is the adsorption of foreign particles by
opsonin proteins such as immunoglobulins, blood serum proteins, and complement proteins.
Subsequently, macrophages may bind directly to the opsonised particle, engulf and remove it
from circulation or the complement system may be activated, also leading to phagocytosis [72].
The characteristics of the particle in circulation play an important role in the recognition
process and therefore are extremely important parameters to consider in the design of a
delivery vector. Particles larger than the renal threshold of approximately 5,000 Daltons
(usually greater than 200 nm hydrodynamic radii) are more likely to activate the complement
system and are usually cleared more rapidly than their smaller counterparts. Surface charge,
hydrophobicity, and the presence of certain functional groups are also important, with a more
cationic nature favouring interaction with the anionic blood proteins and enhancing opsoni‐
sation [73].
Initial opsonisation of particles is critical to their subsequent removal, so if opsonisation can
be reduced or avoided, then clearance may be circumvented. An extensively used method to
overcome opsonisation is the utilisation of shielding groups or ‘stealth’ molecules that are
generally long hydrophilic polymer chains. These are typically flexible and charge neutral,
which can block the electrostatic and hydrophobic interactions between opsonins and the
nucleic acid/vehicle complex, improving the stability of the particles in the systemic circula‐
tion. Various polymers have been used including polyacrylamide, poly(vinyl alcohol), poly(N-
vinyl-2-pyrrolidone), and poly ethylene glycol (PEG) [72].
PEG is the most commonly used and effective polymer for stealth molecules; PEG is non-toxic,
non-immunogenic, non-antigenic, highly water-soluble, and FDA approved. PEGylating a
cationic complex shields the positive charge, thereby reducing interaction with blood compo‐
nents, and inhibiting clearance, allowing increased circulation time and opportunity for
vectors to reach their target site. It also reduces non-specific binding to non-target cells and
stabilises particles, reducing aggregation. The increased circulation time is highly desirable for
passive tumour targeting, facilitated by the leaky tumour vasculature. Extravasation of vectors
from the blood stream occurs with retention and accumulation in the tumour site by the EPR
effect. It has been suggested, however, that repeat administrations may sensitise the immune
system to PEG resulting in rapid clearance of PEGylated liposomes from circulation and
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formation of anti-PEG antibodies [74, 75]. However, the validity of the assays used to test for
anti-PEG antibodies have been questioned over flaws and lack of specificity [76].
In order for PEG to properly oppose the attractive forces between the opsonins and the cationic
particle surface, it must have a sufficient surface coverage, which is usually correlated to the
molecular weight, surface chain density, and conformation of PEG. It is generally held that
sufficient stealth character is achieved with a molecular weight of 2,000 Daltons or more, with
loss of flexibility in shorter chains being the probable cause for lack of stealth. As molecular
weight increases, the blood circulation half-life also increases. Surface chain density and
conformation are also important so that adequate surface coverage is achieved to avoid gaps
where opsonins may bind, while also maintaining flexibility in the PEG layer responsible for
the steric hindrance properties. By fine-tuning such properties of PEG, an improved biodis‐
tribution and the pharmacokinetic profile of the therapeutic may be achieved; such tunings
have led to many different PEGylation strategies being developed [72].
3.1. The PEG dilemma
A major problem with the use of PEG for cancer gene therapy is that it may hinder gene
expression by impeding the entry of the delivery system into tumour cells. The initial inter‐
action of cationic delivery systems with cell membranes relies on electrostatic association, so
masking by PEG may have an unfavourable effect. Further to this, the improved stability of
PEGylated particles disrupts membrane fusion and may reduce the effects of fusogenic
peptides either during cell internalisation or for endosomal disruption. The term ‘PEG
dilemma’ was coined to describe the balance that must be struck between availing of the
beneficial characteristics that PEG provides while not being limited by them. Appropriate
vector design must ensure that an appropriate balance is struck between the facets that make
PEG an attractive supplement to a vector and those that limit its effectiveness [77].
Various strategies have been employed in order to overcome the problems posed by the PEG
dilemma. Once the PEGylated vector has survived in circulation and reaches its target cell, the
PEG chain becomes redundant. By removal or detachment of PEG from the surface of the
vector, interaction with the cell membrane can occur and initiate internalisation. One strategy
that has gained much attention is the addition of targeting ligands to PEG that bind to cell
surface receptors exclusive to the target cells, limiting endocytosis of the PEGylated delivery
system to the target cells [78]. However, this may involve the introduction of a charged moiety
onto the PEG, reducing the effectiveness of PEG in evading clearance. The bulky PEG chain
may also still hinder the gene delivery system overcoming the various intracellular barriers
discussed above. Therefore, the design of a detachable or reversible PEGylation has resulted
in ‘smart’ delivery systems that can exploit different aspects of the intracellular or extracellular
tumour environment, including pH, enzyme complement, or reduction, while also functioning
as a targeting tool to direct vectors to tumours [79, 80].
3.2. pH-sensitive PEG linkers
Using linkages such as ester and hydrazine bonds, which are stable in circulation but hydro‐
lysed in acidic conditions, is a promising way of creating a detachable PEG. The acidic tumour
microenvironment may cleave off the PEG chain, thereby releasing the therapeutic at the target
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site and allowing interaction of the cationic delivery system with cell membranes, initiating
internalisation. Alternatively, the acidic pH within the endosome may also serve to cleave PEG
from the delivery system after receptor-mediated endocytosis. This will unmask the vector
allowing endosomal escape by, for example restoring fusogenic activity, facilitating cytosolic
delivery and subsequent gene expression [79]. Fella et al. described a targeted polyplex system
with PEG attached via an acid labile hydrazone linkage that afforded a 14-fold increase in
transgene expression in HUH7 hepatocellular carcinoma tumours compared to the non-acid
sensitive formulation. The system was able to protect the vector in the systemic circulation,
facilitate entry to the cells via EGF-receptor mediated endocytosis, and exploit endosomal pH
to execute the removal of PEG, which permitted release of the vector from the endosome [81].
3.3. Enzymatic cleavage of PEG
Various proteolytic enzymes are known to be secreted into the extracellular environment by
cancer cells. The knowledge of specific enzymes and their substrates can then be exploited to
tether PEG to a vector via an appropriate enzyme-cleavable linker. Matrix metalloproteinases
(MMPs) are a family of proteases commonly secreted by tumours, degrading the extracellular
matrix facilitating growth and progression of tumours [82]. Li et al. took advantage of the
presence of MMP-7 proteases in the extracellular environment by functionalising polymeric
nanoparticles with PEG via a MMP-7 cleavable linker for delivery of anti-luciferase siRNA.
The authors reported a 2.5-fold increase in transfection efficiency in MDA-MB-231 breast
cancer cells in the presence of MMP-7 in vitro compared to transfection efficiency in the absence
of MMP-7 [83]. These results, however, would need to be further reinforced with in vivo studies
in order to fully assess the pharmacokinetic profile of this system.
3.4. Reduction-sensitive PEG linkage
A reduction-sensitive linkage may be used to attach PEG to a vector using disulphide bonds.
These bonds are susceptible to reduction by glutathione (GSH), a peptide with various
functions within the cell such as antioxidant defence, metabolic processes, and regulation and
maintenance of cellular redox status. The intracellular concentration of GSH is three orders of
magnitude higher than in the extracellular compartment [84], which allows for reduction of
the disulphide bonds and detachment of the bulky PEG chain once the functionalised vector
is inside target cells. Alternatively, extracellular reduction may occur through the action of
thiol-containing cell surface receptors [85]. Lei et al. described a targeted delivery system
functionalised with PEG attached via a disulphide linkage. Polyethylenimine (PEI) nanopar‐
ticles that were functionalised with a reduction-sensitive linked PEG were twice as potent as
their counterparts that lacked the reduction-sensitive linker in terms of GFP and RFP reporter
gene delivery in vitro and in vivo in U87 glioblastoma tumours [86].
3.5. Copolymers
While the use of a cleavable linker for PEGylation has shown promise for gene delivery, issues
may arise if the linker is not accessible for cleavage due to the shielding action of PEG. The
nature of polymers renders them easily modifiable; changing the characteristics of the PEG
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polymer itself by forming crosslinks may produce a degradable copolymer suitable for
controlled release [79]. Fan et al. reported on a copolymer that comprised polyethylene glycol
5000 (PEG114), Vitamin E (VE), and thioctic acid (TA), termed PEG114:VE:TA, which assem‐
bled into micelles with poly-disulfide crosslinks [87]. The copolymer resulted in improved
thermodynamic and kinetic profile of the anticancer drug paclitaxel. Reduction of the disul‐
phide crosslinks occurred in response to glutathione causing rapid disassembly of the micelles
and accelerated drug release that resulted in approximately 3-fold higher plasma concentration
than the non-crosslinked micelles leading to increased drug accumulation in the SKOV-3
human ovarian cancer xenograft mouse model. Although this study did not deliver gene
therapy, it demonstrates the potential of modifying polymer crosslinks to achieve desirable
characteristics for drug delivery.
The production of copolymers, which combine the characteristics of more than one polymer,
has shown promise where a balance is struck between PEGylation and copolymer reducible
characteristics. Recently, Lai et al. presented a reducible copolymer comprising poly(ethylene
oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide)-SS-P[Asp(DET)] (P(EPE)-SS-
P[Asp(DET)]), which possesses a redox potential-sensitive disulfide linkage between the
P(EPE) polymer and the cationic block P[Asp(DET)]. The copolymer was used to deliver the
pGL4 DNA vector for luciferase expression, and a 2-fold increase in transfection efficiency was
observed compared to delivery with non-reducible copolymer counterparts in MDA-MB-231
breast cancer cells in vitro [88]. However, much work is yet to be done to elucidate the exact
characteristics and polymer design needed to produce optimal transfection efficiencies.
Systems that combine two or more mechanisms for masking delivery vectors while improving
uptake have been investigated, with PEG being combined with other polymers or peptides.
Huang et al. designed a multifunctional delivery system that uses a combination of an MMP-
sensitive linkage, a pH-sensitive mask to quench the cationic charge of nona-arginine (R9), and
PEG to improve steric stabilisation in circulation [89]. The masking peptide was pH-sensitive
with an isoelectric point (pI) of 6.4, affording the masking peptide a negative charge at
physiological pH, which interacts with the cationic R9 cell-penetrating peptide (CPP). How‐
ever, a tumour’s acidic environment neutralises the masking peptide, allowing the cationic
nature of R9 to come to the fore. Cleavage of the PEG by MMP-2 allowed the CPP-cargo
complex to enter cells. The authors used in vivo imaging to demonstrate the specificity of these
nanoparticles to target human hepatocellular carcinoma cell (BEL-7402) xenografts.
Although PEGylation provides a means of enhancing circulation times, allowing vectors to
reach their target site, reliance on the EPR effect as a means of passive targeting may not be as
reliable as initially thought. The variability displayed in tumour biology as well as the
disordered and discontinuous tumour vascular structure means that the accumulation of
delivery vectors by the EPR effect may not give a tumour-wide distribution. Although it may
give an added advantage, total reliance on the EPR effect cannot give reliable results and so
there is a need for an active targeting strategy [90].
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4. Targeting in non-viral systems
Early approaches to gene therapy involved direct introduction of genetic material into locally
accessible tumours. While this proved useful in some cases, the invasive nature of these
methods renders them impractical for internal and disseminated tumours. Therefore, a
systemically administered cancer gene therapy vector that can target tumours is ideal.
Traditional chemotherapeutic cytotoxic drugs cause such harsh and debilitating side effects
because they affect rapidly dividing cells and do not differentiate between normal or cancerous
cells. In order to avoid these off-target effects, it is necessary to target the therapeutic directly
to the cancer cells without affecting normal healthy cells. Improved knowledge of cellular,
metabolic, and signalling pathways essential for tumour growth has led to the identification
of targets on cancer cells [91]. Different types of cancerous cells tend to have distinct charac‐
teristics, which set them apart from normal cells, meaning that a range of potential molecular
targets exists that can be targeted to direct gene therapy towards tumours. Cancer cells
typically overexpress certain proteins on their surface, which may be exploited through
targeting strategies; commonly overexpressed proteins include integrins [92], transferrin
receptors [46], epidermal growth factor receptors (EGFR) [93], folate receptors [94], and
proteoglycans [95], and targeting such receptors has been found to increase the specificity and
efficacy of drug delivery, while reducing side effects [96]. Active targeting using ligands that
target overexpressed receptors specific to cancer cells is therefore an attractive targeting
strategy for systemically administered non-viral gene delivery and much research has focused
around this.
4.1. Targeting ligands
Through phage display techniques, ligands for specific receptors commonly overexpressed on
cancer cells have been successfully identified and incorporated into vectors [97]. When the
delivery vector reaches the tumour environment, the overexpressed receptors bind the ligand
on the surface of the vector and it is subsequently internalised via receptor-mediated endocy‐
tosis. This strategy serves to both target the cells and facilitate uptake by cells, but the endocytic
pathway used can depend on the targeting ligand and cell type [98]. RGD peptide is a
commonly used peptide targeting ligand. It is a tripeptide of Arg-Gly-Asp that was derived
from fibronectin, which mediates cell attachment. RGD peptide is involved in cell adhesion to
cell surface integrins [99]. Integrin receptors, such as αvβ3 integrin and related αv-integrins,
are commonly upregulated on the surface of angiogenic endothelial cells and can have a
profound effect on the ability of tumours to survive and progress through regulation of
stemness, metastasis, and resistance [100]. This activity makes integrins valuable for targeting
aggressive cancers and various strategies have been used to incorporate RGD into non-viral
delivery systems for targeting angiogenic tumours [101]. Kim et al. presented a tumour-
targeting, RGD-conjugated, bio-reducible polymer for the delivery of vascular endothelial
growth factor (VEGF) siRNA. The RGD-functionalised vectors showed 20–59% higher cellular
uptake in MCF-7 breast cancer cells and PANC-1 pancreatic cancer cells compared to non-
targeted vectors. In addition, MCF-7 and PANC-1 cancer cells had significantly reduced VEGF
gene expression (51–71%) and cancer cell viability (35–43%) compared with control [102]. Nie
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et al. described a dual functionalised system that boasts two targeting ligands, namely RGD
and B6 peptide, which target transferrin receptors. Transfection efficiency of the dual targeting
system resulted in 8- and 4-fold higher luciferase reporter gene expression compared to single
targeted control formulations with either B6 or RGD in DU145 and PC3 prostate cancer cells,
respectively [103].
When formulating a targeted non-viral gene delivery system, there are a number of factors to
be considered that may have an effect on the overall efficiency of the delivery system, such as
ligand density and positioning on the surface of the vector, vector size, and choice of targeting
ligand [90]. Vector ligand density should be optimised to ensure efficient binding to receptors.
Furthermore, the binding of a ligand to its substrate may facilitate binding of neighbouring
receptors in a thermodynamically favourable way [104]. In addition, the strategies used to link
the targeting moieties to vectors, as well as many other factors including relative specificity,
expression of target receptors, and physiological factors need to be considered in order to
improve effectiveness and avoid interference or loss of biological activity [105].
One such problem with active targeting is that it is dependent on the expression of certain
receptors by tumour cells. In breast cancer, oestrogen, progesterone, and human epidermal
growth factor (HER) receptors have been identified and targeted. However, 15% of breast
cancers, termed triple negative, are defined by a lack of these receptors. Absence of these
receptors makes such cancers difficult to target and treat, hence patients with triple-negative
disease have poorer prognoses [106]. Therefore, there is a need for a more general targeting
strategy that targets the common characteristics of cancer cells and is not reliant on the
expression of any one receptor. This would also broaden the scope of disease states that may
be treated using any individual gene therapy strategy, making them more marketable for the
pharmaceutical industry. Additionally, drug resistance can develop if mutation of cancer cells
affects the expression of the target receptors. The receptors may be down-regulated resulting
in reduced targetability and subsequent reduced cellular uptake of the vectors, or conversely
up-regulation of receptors could render the vector inefficient. Receptors may also be expressed
in different isoforms, altering their recognition of the targeting moiety [107]. Moreover,
heterogeneity of tumours may result in different levels of receptor expression within a single
tumour [108].
Although ligand-targeted vectors have proven to be safe and efficacious in preclinical models,
it has not yet been unambiguously proven that targeting ligands contribute to the efficacy of
vectors, and it seems that targeting ligands do not cause localisation within the target tissue,
but rather provide benefits in terms of internalisation to target cells and retention at the target
site once the delivery system has arrived [109]. While this method of targeting may enhance
non-viral gene delivery systems, it has not completely met expectations and other targeting
strategies have been explored.
4.2. Targeting at the transcriptional level
In an attempt to overcome these problems with the targeting of proteins expressed by cancer
cells, it has been suggested that targeting the upstream genetic causes of dysregulated genes
may be more successful [110]. Regulation of gene expression at the transcriptional level for
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cancer gene therapy can occur in a cell-specific manner with a focus on tissue-specific and
tumour-specific promoters, or alternatively the use of inducible promoters, which allow gene
expression to be controlled exogenously by factors such as heat or radiation. The major
drawback with tissue-specific promoters, however, is that toxic gene expression occurs in all
cells in the tissue, both healthy and cancerous, which limits use of this method to tissues that
are not critical to the survival of the patient such as thyroid or prostate [111]. Use of inducible
promoters to drive transgene expression requires the activation by exogenous factors, but the
tumour specificity that this strategy affords may be useful in supplementing the potency of
other therapies, such as the use of a radiation-inducible promoter for enhancement of iNOS
transgene expression [112]; this dual approach to therapy can limit toxic effects in normal cells.
However, for simplicity, we will focus solely on tumour-specific promoters.
The complex interplay of various factors involved in gene expression is often altered in cancer
cells, and through exploiting this genetic signature of cancer, reduced off target effects and
toxicity should result. Certain genes are upregulated in cancer through the over activation of
transcription factors, which activate the upstream promoter of these genes. This can then be
exploited to give tumour-specific targeting by using promoters that are activated by tran‐
scription factors known to be overexpressed in cancer cells to drive expression of the transgene
in tumour cells only. Tumour-specific promoters are sub-categorized as follows: cancer specific
promoters, tumour-type specific promoters, tumour microenvironment-related promoters,
and tumour vasculature-related promoters, and are extensively reviewed by [113] and [114].
4.2.1. Cancer-specific promoters
The identification of genes that are expressed in cancer cells only may lead to targeting of
cancer gene therapy in a broad sense regardless of cancer type. One such example is telomerase,
involved in telomere maintenance, which is considered crucial in the progression and
immortalisation of cancer cells and is expressed in the vast majority of cancers [115]. Telomer‐
ase expression is regulated by the human telomerase reverse transcriptase subunit promoter
(hTERTp), which was recently used by Xie et al. in a non-viral delivery system. The hTERTp
promoter was used to drive expression of a transgene amplification vector VISA (VP16-GAL4-
WPRE integrated systemic amplifier) to target a phosphoprotein that is enriched in astrocytes
(PEA-15) in advanced breast tumours. PEA-15 is known to affect signal-regulated kinase (ERK)
in the cytoplasm, thereby inhibiting cell proliferation and inducing apoptosis [116]. Transgene
expression was found to be highly specific, inducing cancer-cell killing in breast cancer cell
lines (T47D, MCF-7, MDA-MB-231, MDA-MB-468, MDA-MB-361, MDA-MB-453, BT474, 4T1,
SKBR-3) in vitro without affecting normal mammary epithelial cells (184A1 and MCF-10A).
Furthermore, an in vivo study in a MDA-MB-231 xenograft mouse model demonstrated that
the expression of PEA-15 driven by the hTERTp driven VISA vector prolonged mouse survival
more effectively than PEA-15 driven by cytomegalovirus (CMV) promoter whilst showing no
acute toxicities. The authors demonstrated that the use of the hTERT promoter achieved
targeting and selective cell kill in triple negative MDA-MB-231 breast cancer cells, a selectivity
that was lacking when transgene expression was promoted by the CMV promoter [116].
Gene Therapy - Principles and Challenges72
Survivin is a protein that functions in the inhibition of apoptosis, therefore, its overexpression
in cancer cells can facilitate uninhibited growth. It is known to be upregulated in cancer cells
and expression is controlled by various transcription factors including nuclear factor kappa B
(NF-kB), Runx2 and the Ras family that bind to the survivin promoter, triggering expression
[117, 118]. The survivin promoter (pSURV) has therefore been incorporated into gene delivery
systems to drive transgene expression preferentially in cancer cells. Qu et al. used pSURV to
drive the expression of the herpes simplex virus thymidine kinase (HSVtk) gene for suicide
gene therapy. The authors used pSURV/GFP to demonstrate that gene expression occurred in
HepG2 hepatocellular carcinoma cells, while no gene expression was observed in LO2 normal
human liver cells. Apoptotic rates of up to 55% were achieved in HepG2 cells with pSURV/
HSVtk demonstrating the possibility of this system for suicide gene therapy. However, further
in vivo studies need to be carried out to properly assess the targeting ability of this system [119].
4.2.2. Tumour-type specific promoters
Many different types of cancer overexpress various genes, which are characteristic of that
tumour type, and the promoters responsible for this expression can then be exploited for
tumour-type specific targeting. Osteocalcin is a protein normally found in the bone matrix but
has been found to be elevated in cancers such as ovarian and prostate cancer and is associated
with the progression and formation of bone metastases; McCarthy’s group used the human
osteocalcin promoter (hOC) for tumour-limited gene expression. It has been shown that hOC
has strong promoter activity in cancer cells, with transcription factors such as Runx2 involved
in gene upregulation [120, 121]. In this case, hOC was used to drive the expression of inducible
nitric oxide synthase expression in PC-3 and DU145 prostate cancer cells. The authors
demonstrated significant delay in tumour growth with no toxic side effects in vivo, highlight‐
ing the potential for hOC to target prostate cancer tumours [122]. The advantage of using this
tumour-type specific promoter is that it may facilitate the targeting of the primary tumour, as
well as disseminated metastatic lesions that are often the most aggressive and hardest to treat
forms of cancer. Figure 2 represents the targeting strategy of a tumour-type specific promoter
that is activated in cancerous cells but not in normal cells.
Figure 2 summarises active internalisation of gene delivery vector and initiation of transgene
expression in a non-transformed and a transformed cell. Gene delivery vectors are commonly
functionalised using an antibody that targets HER-2 [123], while the human osteocalcin
promoter has been employed to drive inducible nitric oxide synthase gene expression in
prostate and breast cancer cells [122].
4.2.3. Tumour microenvironment-related promoters
The tumour microenvironment provides a unique environment that provides ideal conditions
for growth and progression of tumours. Hypoxic conditions are often associated with chemo-
and radio-resistance in tumours, and hypoxia is thought to be a key element for the cancer
stem cell niche [124]. Various genes have been identified to be upregulated in the hypoxic
environment with hypoxia response elements (HREs) working in concert with transcription
factors, such as HIF-1, to activate transcription in response to hypoxia. Fujioka et al. reported
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the construction of a vector combining a hypoxia response promoter with the CMV promoter
(HRE-CMV) that resulted in a 2-fold increase in apoptotic gene expression compared to
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Figure 2. Targeted therapeutic transgene expression using affibodies and a tumour-specific promoter.
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expression driven by CMV alone. In vivo, BCL-2 shRNA activity driven by the HRE-CMV
promoter in hypoxic colon 26 tumours resulted in tumour volume reduction that was signif‐
icantly greater than when bcl-2 shRNA was driven by CMV alone [125]. Although this study
demonstrates the action of the HRE promoter for treatment in hypoxic tumours, the authors
used intra-tumoural injections to deliver the vector, which does not give an indication of the
tumour targeting specificity of this strategy.
4.2.4. Tumour vasculature-related promoters
The ability of tumours to trigger angiogenesis for increased tumour blood supply has been
associated with more aggressive tumours, metastases, and poor prognosis. Identification of
the genes involved in this process has led to the use of promoters that can be exploited for
targeting. One such example is VEGF, which has been shown to have a major role in tumour
angiogenesis by activating tyrosine kinase receptors VEGFR1 (Flt-1) and VEGFR2 (kinase
insert receptor (KDR) in humans/Flk-1 in mice). KDR was found to be overexpressed in
activated endothelial cells of newly formed vessels and strongly associated with invasion and
metastasis in human malignant diseases [126]. Wang et al used the KDR promoter to drive
thymidine kinase (TK) gene expression, which activated the prodrug ganciclovir (GCV) for
suicide gene therapy. The authors demonstrated that the KDR promoter and TK/GCV showed
a targeted killing effect on transfected human umbilical vein endothelial cells (HUVEC). Cells
transfected with KDR-TK were 2- to 5-fold more sensitive to GCV compared to non-transfected
HUVEC and HepG2 cells [127]. Again, however, confirmation of these impressive in vitro
results in an in vivo setting using systemic delivery is required to validate tumour targetability
and efficacy of the suicide gene/prodrug system.
5. RNA interference
Most of the strategies of cancer gene therapy discussed so far have involved introduction of
therapeutic transgenes. An alternative strategy that is gaining considerable attention in the
cancer gene therapy field involves inhibiting expression of problematic genes. Inhibition of
gene expression can be facilitated by RNA interference (RNAi) that binds to mRNA. RNAi,
discovered by Fire and Mello in 1998 [128], can be defined as a mechanism of gene-silencing
produced by small RNAs. These RNAs include endogenous miRNA and exogenous siRNA or
shRNA and their gene silencing activity is highly dependent on gene sequence [129]. These
small RNAs then recruit cellular proteins, such as the RNA-induced silencing complex (RISC),
to elicit their effect either through degradation of the mRNA or blocking the translation of
mRNA [130, 131]. RNAi interference is therefore a highly attractive approach to cancer gene
therapy and is currently a major research focus.
5.1. siRNA and shRNA
siRNA is a short (usually 21-bp) double-stranded RNA with phosphorylated 5’ ends and
hydroxylated 3’ ends with two overhanging nucleotides. siRNA exerts its effect by directly
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incorporating into RISC, where its guide-strand binds to and cleaves the complementary
mRNA with a perfect match. The cleaved mRNA is subsequently released and the siRNA
guide-strand-bound RISC is free to bind to another mRNA and start a new round of cleavage
[132]. However, the short half-life of siRNA has resulted in production of shRNA, which has
been developed as an alternative RNA molecule. Transcription of shRNA occurs in the nucleus
from an expression vector that bears a short double-stranded DNA sequence with a hairpin
loop. This shRNA transcript is then processed by RNase enzymes and incorporated into RISC
in the cytoplasm [133].
The use of siRNA and shRNA to silence unfavourable genes that are overexpressed in cancer
has gained much attention. Multidrug resistance (MDR) genes, responsible for resistance to
chemotherapeutics have been problematic in the treatment of cancer and associated with poor
prognosis. By silencing these genes using siRNA, it has been possible to improve response to
conventional treatments. For example, Chen et al. used siRNA to silence the MDR1 gene in
doxorubicin resistant MCF-7 breast cancer cells, which resulted in 85–90% reduction in MDR1
gene expression and subsequently sensitisation of 70% of cells to doxorubicin [134]. Another
approach is to target and silence pro-angiogenic genes such as the Notch pathway. Yang et al.
used a non-viral delivery system to deliver siRNA for silencing the Notch-1 gene in breast
cancer and found that transfected MDA-MB-231 cells exhibited significantly decreased
expression of Notch-1, inhibited cell proliferation, and increased cell apoptosis [135]. One
advantage of using siRNA to down-regulate overexpressed proteins is that non-specific
delivery is often less toxic than the delivery of plasmid DNA that encodes genes such as IL-2
and TNF-alpha. However, to limit any toxicity that does exist, many groups have added
targeting ligands to the delivery systems to increase tumour specificity [136].
5.2. MicroRNA
MicroRNAs (miRNA) are highly conserved short non-coding RNAs that negatively regulate
a wide range of physiological processes at the post-transcriptional level including apoptosis,
proliferation, and migration [137]. Initially, miRNA is transcribed in the nucleus as a primary
transcript (pri-miRNA), which is processed to give a two-nucleotide overhang at its 3’ and is
termed a pre-miRNA. Pre-miRNA is subsequently exported to the cytoplasm where it is
further cleaved and mature miRNA is loaded into RISC to elicit its effect [138]. miRNAs can
be either oncogenic or tumour suppressive in nature and as a result, may be overexpressed
(e.g., miR-132, miR-20, and miR-17-92 family) or underexpressed (e.g., miR-34a and miR-126)
in cancer cells making them targets for cancer gene therapy. A vast amount of information has
been obtained in recent years on many different miRNAs and their role in cancer and with
cancer stem cells, and by characterising their function, it may be possible to exploit them in
cancer gene therapy [139, 140].
A single miRNA may have several varied targets to which it could bind and bring about gene
silencing. miRNA-34a, known to be down-regulated in various cancers, has been shown to be
a potent tumour suppressor that has various targets including the Notch pathway, BCL-2,
survivin, c-Myc, and c-Met transcription factors [141]. Hu et al. demonstrated the value of
miR-34a-mediated tumour suppression with the in vivo systemic administration of a non-viral
Gene Therapy - Principles and Challenges76
miR-34a delivery system. Nanoparticles were used to deliver the miR-34a using a tumour-
targeting and penetrating bifunctional CC9 peptide (CRGDKGPDC) conjugated to β-cyclo‐
dextrin-polyethylenimine in a PANC-1 pancreatic cancer xenograft model; the miR-34a-
loaded particles significantly inhibited tumour growth and induced cancer cell apoptosis [142].
Conversely, the inhibition of some miRNAs using complementary miRNA antagonist
oligonucleotides (anti-miRNAs) can be an attractive gene therapy strategy to neutralise
miRNA function. miR-132 acts as an angiogenic switch at the endothelium, inducing tumour
neovascularization. Anand et al. reported the systemic administration of anti-miR-132
containing liposomes incorporating an integrin αvβ3-targeting cyclic RGD peptide to inhibit
angiogenesis [143]. The authors demonstrated that anti-miR-132 blocked the action of mi-132
on angiogenesis induced by a VEGF-secreting ID-8 ovarian carcinoma in mice, and signifi‐
cantly reduced tumour burden and angiogenesis in an MDA-MB 231 xenograft model of
human breast carcinoma when compared to treatment with scrambled miR-132. There is a
huge potential of miRNA therapeutics for cancer. However, miRNA gene therapy is still in its
infancy and more research is required to elucidate the exact pathways and possible targets
available.
The active targeting of cancer gene therapy is hugely important for efficiency and safety. Yet
despite the plethora of characteristics that can be targeted, active targeting remains elusive in
many non-viral gene delivery systems. A move towards a combination of targeting strategies
in one delivery system may hold promise for improved specificity using non-viral vectors.
6. The future: Molecular engineering
Strategies involving PEGylation and the use of targeting ligands have shown great promise
for cancer gene therapy in overcoming certain hurdles, but in order to maximise the efficiency
of non-viral delivery, vectors must have the ability to overcome all the barriers to gene delivery.
Recent research in the field has focused on the development of vectors for nucleic acid delivery
that efficiently evade the barriers to gene delivery highlighted above, and provoke adequate
transgene expression in vivo following systemic delivery.
6.1. Multifunctional Envelope-type Nano Devices (MENDs)
Harashima et al. presented a multifunctional envelope-type nano device (MEND) that was
produced on the concept of ‘programmed packaging’ with a rational design to overcome
barriers to delivery and assembly into nano-sized vectors. Generally, a MEND comprises a
DNA core condensed using a cationic polymer such as poly-L-lysine (PLL), which is wrapped
in a separate lipid envelope fortified with various functional attachments including targeting
ligands, PEG, and groups facilitating cellular uptake and endosomal escape [144]. One of the
first MEND systems described consisted of a PLL DNA condensing core, surrounded by a lipid
envelope, and functionalised with stearylated octaarginine (R8) to promote cellular uptake to
deliver anti-luciferase siRNA [145]. The gene silencing effect of the MEND was found to be
comparable to that of the transfection reagent Lipofectamine 2000, without any detectable
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cytotoxicity and further optimisation of this system to include protamine as the DNA con‐
densing agent resulted in a 70% silencing effect in transfected COS7 fibroblast cells.
The nature of the MEND system renders it relatively easy to modify in order to optimise
transfection efficiency. When the lipid component of egg phosphatidylcholine (EPC) and
cholesterol were replaced with the fusogenic lipids DOPE and cholesteryl hemisuccinate
(CHEMS), respectively, an overall 2-fold improvement was observed due to the optimisation
of the lipid component [146]. Furthermore, functionalization of MEND with octa-arginine R8
(R8-MEND) for enhanced cellular uptake resulted in a transfection efficiency of more than 80%
in HeLa cells [147]. The addition of pH-sensitive endosomal escape motifs to MEND, such as
INF7 derived from the HA2 protein of the influenza virus envelope, has also proven beneficial,
and the combination of INF7 with R8 resulted in the production of R8/INF7/MEND. In vivo
administration of R8/INF7/MEND to ICF mice produced luciferase expression 240-fold higher
in liver and 115-fold higher in spleen than that of R8-MEND alone, demonstrating the
importance of optimising functionality of the MEND system [148].
In a similar approach, the pH-sensitive fusogenic peptide GALA was incorporated into a
MEND system as an endosomal escape enhancer in a system that comprised of R8 and an
MMP-cleavable PEG functionality. Increased gene silencing effect was observed for delivery
of anti-luciferase siRNA in HeLa-luc cells in vitro when compared to an unmodified MEND
[149]. In addition to this, an in vivo study using a HT1080-luc xenografted model demonstrated
that the cleavable PEGylated GALA/R8/MEND exhibited efficient luciferase gene knockdown
in comparison to PEG-MEND, which was unable to cause any gene knockdown.
Incorporation of targeting motifs has also proved useful in MEND systems. The addition of
RGD peptide to MEND, which is a targeting ligand for integrins, resulted in significant tumour
growth delay in OS-RC-2 human renal carcinoma bearing mice when RGD-MEND was used
to deliver anti-VEGF siRNA in vivo [150]. GALA peptide was also used as a targeting ligand
for sialic acid-terminated sugar chains on pulmonary endothelium as reported by Kusumoto
et al. [151]. Following intravenous administration of GALA-MEND delivering antiCD31
siRNA in vivo, approximately 50% inhibition of lung metastasis in a Murine melanoma B16-
F10 mouse model was observed when compared with control groups. Examples of MENDs
and the various functionalities that have been employed are detailed in Table 1.
Name Condensing
material and
nucleic acid
cargo
Lipid Envelop Endosomolytic
component
Nuclear
localisation
component
Other functional
groups
Activity
R8/INF7-
MEND
Protamine
(plasmid DNA
for luciferase
transgene
expression)
Egg
phosphatidylcholine
(EPC), cholesterol
(Chol), 1,2-dioleoyl-
sn-glycero-3-
phosphocholine
INF7 peptide
derived from N-
terminal domain
of the HA2
protein influenza
virus envelope
Protamine - Luciferase
transgene
expression levels
240-fold higher in
liver and 115-fold
higher in spleen
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Name Condensing
material and
nucleic acid
cargo
Lipid Envelop Endosomolytic
component
Nuclear
localisation
component
Other functional
groups
Activity
(DOPC), and
dioleoylphosphatidyl
ethanolamine (DOPE)
than that of the
R8-MEND in vivo
[148].
GALA/
PPD-
MEND
Stearylated
octahistidine
(STR-H8) (anti-
luciferase
siRNA
condensation)
DOPE, 1,2-dioleoyl-3-
trimethylammonium-
propane(DOTAP),
Chol
pH-responsive
fusogenic GALA
peptide derived
from HA2
N/A (MMP-cleavable
PEG)
Intratumoural
injection of PPD/
GALA- MEND
HT1080-luc into
human
fibrosarcoma
mouse xenografts
resulted in more
efficient luciferase
gene silencing
compared with
unmodified
MENDs in vivo
[149].
RGD-
MEND
Protamine (anti
VEGF siRNA)
YSK05 (pH dependent
cationic lipid), 1-
Palmitoyl-2-oleoyl-sn-
glycero-3-
phosphoethanolamine
(POPE), Chol
YSK05 (YSK05
consists of two
linoleyl fatty acid
chains and a
tertiary amino
group, which are
responsible for
pH-responsive
fusiogenicity in
endosomes)
N/A Cyclo (RGADPK)
(cRGD) peptide
ligand for αVβ3
integrin
PEG
Significant
tumour growth
delay was
observed in OS-
RC-2 human
renal carcinoma
bearing mice
when RGD-
MEND was used
to deliver anti-
VEGF siRNA in
vivo [150].
GALA-
MEND
Polyethylenimin
e (PEI) (anti-
CD31 siRNA)
EPC, Chol GALA peptide N/A GALA peptide
(ligand for sialic
acid-terminated
sugar chains on
pulmonary
endothelium)
PEG
Murine
melanoma B16-
F10 lung
metastasis
significantly
inhibited by
approx. 50%
compared with
control groups
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Name Condensing
material and
nucleic acid
cargo
Lipid Envelop Endosomolytic
component
Nuclear
localisation
component
Other functional
groups
Activity
following
intravenous
administration of
GALA-MEND
delivering anti-
CD31 siRNA in
vivo [151].
Table 1. MEND non-viral delivery systems, their components and applications to gene therapy
The potential of controlled intracellular delivery using the MEND system was also highlighted
by Toriyabe et al. who used stearylated-octahistidne (STR-H8) as a pH-responsive component
to facilitate the efficient release of siRNA in the cytoplasm [152]. STR-H8 was used to complex
anti-luciferase siRNA and delivered using a conventional R8/GALA functionalised MEND.
The authors demonstrated that luciferase gene knockdown was significantly higher in HeLa-
GL3 cells treated with the STR-H8 MEND than with a MEND containing stearylated octaar‐
ginine (STR-R8) to condense the siRNA. This may be explained by more efficient de-
condensation and release of siRNA from STR-H8 in the cytoplasm, which was confirmed by
a RiboGreen assay showing siRNA release efficiency from STR-H8 was much higher than
siRNA release from STR-R8 at pH7.4 (intracellular pH). It is clear, therefore, that PEGylation
and unpackaging of DNA are important considerations in the development of MEND systems,
and with further optimisation and characterisation, MENDs have great promise as effective
non-viral gene delivery agents.
6.2. Bio-inspired systems
Viral vectors still remain the most efficient gene therapy delivery vehicles with no non-viral
delivery system producing comparable gene delivery potencies. Viruses have evolved
naturally to infect and transfer their genetic material into host cells [153]. Understanding the
various mechanisms by which viruses elicit delivery of genetic material has led to exploitation
of viral peptide motifs by gene therapists and molecular engineers [154]. Functional peptide
motifs derived from viruses have been engineered and incorporated into a wide range of bio-
inspired non-viral delivery systems with great success, thereby benefiting from the viruses’
expertise, while circumventing immunogenicity and safety concerns associated with viruses
[35, 154]. Peptides are an attractive alternative to polymer and lipid-based non-viral vectors
as they are less toxic, easily synthesised, and only weakly activate the complement system
therefore enhancing safety [155]. The main peptides of interest are generally classified
according to their function, i.e., DNA condensing peptides, cell penetrating peptides, endo‐
somolytic peptides, and nuclear location sequences [156].
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6.3. DNA-condensing peptides
Cationic peptides containing lysine or arginine residues interact electrostatically with the
negatively charged phosphate backbone of DNA, condensing and packaging DNA into
complexes with a net positive charge, which protects DNA from degradation and allows
interaction with cell membranes [157]. Examples include histones, including H2A, which are
natural basic proteins [158], µ (mu) peptide derived from adenovirus [159], and TAT peptide
from HIV-1 [160]. Condensing peptides alone have a limited role because they cannot over‐
come many of the barriers to gene delivery; although some peptides, such as TAT, have cell
penetrating properties, which makes them more attractive options in vector development
[161]. However, the unpredictable nature of interactions between peptides and nucleic acids
remains an issue and further research is needed for optimisation of vectors [157].
6.4. Cell Penetrating Peptides (CPPs)
Cell penetrating peptides (CPPs) are generally short peptides that have the ability to cross
the cell membrane via various mechanisms including endocytic pathways or through direct
translocation,  without the need for  receptors or  other carriers  [162].  Such peptides have
been shown to deliver various cargoes to a range of cell types; peptide sequences are easily
modifiable  to  optimise  properties  such as  cargo transport  or  subcellular  targeting [163].
Natural  peptides  exhibiting  this  penetrating  activity  include  Penetratin  (RQI‐
KIYFQNRRMKWKK), derived from the third helix of the homeodomain of Antennapedia
[164], and TAT (GRKKRRQRRR) derived from HIV-1 [41]. Both have regions of basic amino
acids and an alpha-helical conformation with the ability to translocate a cargo across cell
membranes, which highlights the potential application of CPPs in gene therapy. Novel CPPs
have  since  been  derived  and  include  peptides  with  a  wide  range  of  structures  and
characteristics; however, generally CPPs are cationic/basic, amphipathic, or hydrophobic in
nature [156].
Amphipathic peptides are composed of both hydrophobic and hydrophilic domains in
primary or secondary conformation. The secondary structure produces an alpha-helical
structure with the hydrophobic residues such as leucine, glycine, or tryptophan localised on
one face of the helix and the hydrophilic residues such as lysine, arginine, or histidine localised
on the other. This amphipathic structure has been shown to be essential for passage across the
cell membranes [165]. Structural changes of amphipathic peptides contribute to their binding
affinity for cell membranes, and insertion of hydrophobic portions of the peptide into the
membrane are important for interaction with the lipid membrane and subsequent uptake [54].
However, although amphipathic peptides have shown much promise, not all CPPs rely on this
amphipathic nature for internalisation. For example, in the case of Penetratin, it is the positive
charges rather than the helical structure that is responsible for cell penetration [166]. Therefore,
increasingly, attention has been paid to developing simple linear peptides rich in cationic
amino acids such as arginine. Cationic CPPs are composed mainly of basic amino acid residues
including arginine, lysine, and histidine [167] and electrostatically bind to various anionic
species present on the extracellular surface of the cell membranes, e.g., lipid head groups or
proteoglycans such as heparin sulphate [168].
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It has been reported that peptides containing arginine residues have stronger cell penetrating
ability than peptides comprising lysine and histidine, with the guanidine moiety possessed by
arginine being held as crucial for cell entry [169]. As a result, arginine-rich peptides have been
extensively researched in order to characterise their activity [170–172]. The discovery that the
basic portion of TAT responsible for the cell penetrating activity is rich in arginine residues
prompted much research into the characterisation of mechanisms involved in the cellular entry
of arginine-rich peptides [41]. It has been elucidated that the exact peptide sequence involved
is not as crucial as the length of sequence and number of arginine residues incorporated, with
between 6 and 15 arginine residues required for optimum activity [54]. In a study carried out
by Wender et al., it was observed that truncated versions of TAT with arginine residues
replaced with alanine exhibited reduced cellular uptake, but a 9-mer oligoarginine peptide
(R9) was 20-fold more efficient than TAT [173]. Further to this, Mitchell et al. used peptides
composed of multiple arginine residues termed oligoarginines, labelled with fluorescein to
demonstrate that negligible cell uptake was exhibited with fewer than 6 arginine residues, but
that when peptides of 7 arginines or more were tested, fluorescence increased as a function of
peptide length up to 15 arginine residues, beyond which no increase in fluorescence was
observed. Peptides containing more than 15 arginine residues can still penetrate cells, although
this happens at a reduced efficiency and with toxicity to cells [169].
CPPs have the ability to enter any cell they come in contact with and this lack of specificity is
problematic for gene therapy [174]. The use of ‘smart’ delivery vectors with ‘activatable’ CPPs
(ACPs) has been explored, where a CPP is connected to a neutralising polyanion via a cleavable
linker, reducing the overall charge and non-specific electrostatic uptake by cells. Enzymes
produced in cancerous cells, such as MMPs, can then cleave the linker and allow the CPP to
enter cancer cells [175]. For example, Mei et al. reported an ACP that includes a masking
sequence of anionic E8 (sequence: EEEEEEEE) to shield the cationic nature of R8 [176]. The
mask was linked to R8 by a MMP-2 sensitive linker; when the ACP nanoparticles were in the
tumour environment, which overexpresses MMP-2, the mask was cleaved exposing R8 to
tumour cells allowing tumour specific uptake. The authors used in vivo imaging to demon‐
strate this, while also showing lower ACP nanoparticle distribution in other tissues.
Another strategy for targeting and cell specificity has focused on the use of cell-penetrating-
homing peptides (CPHPs) [97, 177] that combine targeting and cell penetration abilities. Kondo
et al. described a CPHP known as RLW (peptide sequence: RLWMRWYSPRTRAYG) found
through systematic selection from a random peptide library that had the ability to selectively
target and penetrate A549 non-small cell lung cancer cells via an unknown mechanism thought
to involve specific RLW ligand receptors on A549 cells [178]. Gao et al. demonstrated that when
RLW was anchored onto poly(ethyleneglycol)-poly(ε-caprolactone) (PEG-PCL) nanoparticles
loaded with infrared dye (DiR) cellular uptake was 2-fold higher in A549 cells than in umbilical
vein endothelial cells in vitro [179]. Further to this, in vivo imaging showed the RLW nano‐
particles targeted A549 xenografts specifically over U87 xenografts, with only low levels seen
in normal organs in comparison to PEG-PCL nanoparticles functionalised with R8, which
evoked DiR accumulation in all tissues. The specificity of CHCPs is a great asset; however,
elucidation of the exact mechanism of how CHCPs work and a broader spectrum of activity
may be more attractive so that a peptide may be used to treat more than one cancer type.
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The cargo being carried by the vector must also be considered when designing a vector, as
CPPs interact with various cargoes in different ways. For example, TAT mediates internalisa‐
tion by at least two distinct pathways. Large cargoes, e.g., proteins, enter via caveolae endo‐
cytosis and macropinocytosis leading to endosomal entrapment, whereas small cargoes, e.g.,
peptides, enter slowly by endocytosis and rapidly by transduction by an unknown mechanism
that gives direct access to the cytosol [42]. As endosomal entrapment is a major barrier to
transfection, CPPs have been functionalised with endosomolytic peptides. Liou et al. described
a fusion peptide that combines R9 for cell penetration and hemagglutinin-2 (HA2) for endo‐
somal escape; the resulting vector was tagged with red fluorescent protein (RFP) for imaging
purposes [180]. Significantly more RFP was detected in vitro when A549 human lung carci‐
noma cells were treated with the R9-HA2 peptide in comparison to R9 alone.
Problems with CPPs, such as humoral immune response induction, as seen in studies with
Penetratin [181], and stability need to be addressed. Amino acids exist in different isoforms
with variable susceptibility to degradation by proteases in serum. The L-isoform found in
abundance in nature is sensitive to degradation, but the D-isoform is more resistant due to the
altered stereochemistry that affects protease recognition. The use of the D-isoform of amino
acids has therefore been suggested as a modification to render CPPs protease-resistant,
enhancing stability [182]. However, further characterisation of the structure-activity relation‐
ship of individual CPPs is needed to allow the tailoring of specific CPPs to particular intra‐
cellular targets, optimising efficiency and reducing side effects [183].
6.5. Endosomolytic peptides
The harsh endosomal environment can lead to degradation of peptides and their cargo, as
CPPs, such as TAT and oligoarginines, lack the ability to escape the endosome unaided,
resulting in poor transfection efficiencies [184]. Histidine-rich peptides are usually endoso‐
molytic in nature and can facilitate endosomal escape through the proton sponge where the
protonation of imidazole groups in histidine-rich peptides facilitates buffering of the endo‐
some causing endosomes to swell and burst, releasing their contents [185, 186]. Another
mechanism employed by histidine-rich peptides is the ‘flip-flop’ effect, which may operate
depending on the number of histidine residues or their arrangement in a peptide [187]. In a
study conducted by Lo et al., the addition of 10 histidine residues to TAT increased luciferase
transgene expression up to 7,000-fold in the human glioma cell line U251 in vitro [188].
Bafilomycin A1, a known inhibitor of the proton sponge effect for endosomal escape, in turn
inhibited transfection significantly, supporting the idea that the activity of histidine as an
endosomal escape motif could improve the transfection efficiency of TAT. However, in vivo
administration of the TAT-histidine peptide/DNA complexes to deliver the luciferase reporter
gene into the brain of rats showed 5-fold lower expression than was achieved using PEI 25
kDa/DNA complexes, suggesting more work needs to be done to ensure in vitro results
translate to the in vivo setting. One example of a histidine-rich peptide that has shown great
promise is H5WYG, derived from the HA2 subunit of haemaglutinin (HA) protein of the
influenza virus. H5WYG causes endosomal escape through the proton sponge effect, when
the histidine residues become protonated at around pH 6. H5WYG is unaffected by the
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presence of serum that gives it an added advantage of being suitable for in vivo gene delivery
[189]. Asseline et al. reported a 2-fold increase in luciferase mRNA levels when H5WYG was
added to an antisense oligonucleotide (2’-Ome RNA705) targeting aberrant splicing of
luciferase pre-mRNA in HeLa pLuc705 cells [190].
Fusogenic peptides have also been of great importance in facilitating endosomal escape [191].
Pore formation may be mediated by cationic amphiphilic peptides that bind to the lipid bilayer
of the endosomal membrane, causing internal stress or tension leading to pore formation.
Fusogenic peptides are known to adopt an amphipathic α-helical structure when pH drops to
around 5 within the endosome, causing interaction with the phospholipid membrane and
endosomal disruption [156, 192]. This fusogenic activity also allows these peptides to interact
with cell membranes and facilitate internalisation, giving some fusogenic peptides a dual
function with ability to package nucleic acid to avoid degradation and be delivered into the
cytoplasm of the cell. One such example is RALA (WEARLARALARALARHLARALARAL‐
RACEA), a 30 amino acid fusogenic peptide with a cationic nature [193]. It is composed of a
hydrophilic arginine (R) region that facilitates condensation of anionic complexes, e.g., DNA;
a hydrophobic leucine (L) region that interacts with lipid membranes; and an alanine (A)-rich
region that gives the peptide amphipathicity. This structure allows RALA to maintain α-helical
conformation at low pH, enabling endosomal escape. The design of RALA was informed by
the understanding of two similar peptides, namely GALA (WEAALAEALAEALAEHLAEA‐
LAEALEALAA) and KALA (WEAKLAKALAKALAKHLAKALAKALKACEA), peptides that
were in turn derived from the HA2 subunit of the influenza virus, with GALA being the first
cell penetrating amphipathic peptide demonstrated to possess fusogenic activity [192].
However, GALA carries an overall negative charge and therefore cannot be used for delivery
of DNA alone. KALA was derived by substituting the glutamic acid (E) in GALA with lysine
(K); the resulting derivative was positively charged, and thereby more suitable for delivery of
DNA. This E to K substitution resulted in improved interaction with negatively charged cell
membranes and allowed condensation of negatively charged DNA cargoes [194]. RALA was
derived by substituting lysine residues with arginine (R), which conferred a lower toxicity
[172, 193].
6.6. Nuclear Localisation Sequences (NLSs)
Intracellular trafficking of nucleic acid cargo and entry into the nucleus is crucial for transgene
expression. The use of nuclear localisation sequences (NLS) has proved beneficial in improving
the efficiency of vectors. NLSs help traffic vectors towards the nucleus and facilitate entry
through the nuclear envelope in association with the importin pathway [62]. Classical nuclear
localisation signals, such as the NLSs from simian virus 40 (SV40), large tumour antigen
(PKKKRKV), and Rev peptide (RRNRRRRWRERQRQ), consist of short stretches of basic
amino acids [195]. Such NLSs have the ability to bind DNA in order to facilitate nuclear entry.
Elder et al. used atomistic molecular dynamics to investigate the effect of peptide chemistry
and sequence on DNA binding behaviour, focusing on the NLS from SV40 [196]. By analysing
the conformational entropy and free energy of binding, the authors found that replacing
arginine with lysine reduced binding strength by eliminating arginine–DNA interactions, but
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placing arginine in a less sterically hindered location has little effect on polycation–DNA
binding strength. This strong binding ability of arginine is important for an NLS because
nucleic acids need to be bound and protected from degradation by nucleases in the cytosol
before reaching the nucleus.
Several other proteins derived from viruses are excellent at traversing the intracellular network
and facilitating nuclear import [197]. The TAT, Rev, and Rex proteins of the retroviruses
contain arginine-rich NLSs, which have the ability to shuttle to and from the nucleus. Herpes
simplex virus (HSV) type 1 tegument proteins, known as VP13/14, are also arginine-rich and
act in a similar way [198, 199]. The arginine-rich portion of these proteins is responsible for the
nuclear import, with leucine-rich portions, known as nuclear export signals (NES), being
responsible for the shuttling between the nucleus and cytoplasm. Arginine-rich NLSs have
been shown to use importin β pathway with no involvement of importin α pathway [200].
Importin β is not only involved in nuclear import but is also a potential adaptor for movement
along microtubules, which may enhance trafficking of arginine-rich peptides to the nucleus,
as well as entry to the nucleus [201]. Identification of exact binding sites and utilisation of such
mechanisms may be the key to improving transfection efficiencies for peptide delivery vectors.
Incorporation of such sequences has proven to be useful in vector design. Hatefi et al. dem‐
onstrated that the addition of Rev (RRNRRRRWRERQRQ) to their fusion peptide KALA-2H1-
NLS-TP facilitated cargo delivery to the nucleus by utilising microtubules for nuclear
localisation [186]. Non-classical NLSs, such as M9 from human mRNA binding protein hnRNP
A1, have also shown promise for non-viral vector functionalisation [202]. These NLSs lack
stretches of basic amino acids and do not enter the nucleus via the importin pathway. M9 binds
to the transportin receptor that results in nuclear localisation and has shown the ability to
transport the vector towards the nucleus by shuttling between the nucleus and cytoplasm
[203–205]. These properties make M9 an attractive NLS for gene delivery [65]. A number of
viruses are known to exploit host microtubule machinery to facilitate access to the nucleus
[206], but little is known about the exact mechanisms and binding domains used by viruses,
and further study is required to elucidate exact peptide sequences involved that may be
incorporated into non-viral vectors for rational design to achieve enhanced transfection
efficiencies [207]. For example, the motif sequence contained in the adenoviral capsid hexon
(E3-14.7K peptide: VVMVGEKPITITQHSVETEG) was conjugated to plasmid DNA and
promoted microtubule-mediated transport of the DNA, resulting in 2.5-fold increase in
transfection efficiency in HeLa cells compared to plasmid DNA only [208]. Incorporation of
this sequence into a non-viral vector may therefore improve transfection efficiency.
Problems have been encountered where binding of an NLS with DNA renders the NLS unable
to bind to the importins that allow passage through the NPC. Using a basic NLS to condense
and deliver DNA alone has not been successful because they do not bind DNA strongly enough
and the complexes are generally broken down in the cytoplasm [209]. Covalent conjugation
of an NLS to DNA has been problematic as this may render the NLS or the DNA non-functional,
as demonstrated when covalent bonding of SV40 did not increase nuclear localisation of pDNA
[68]. Various binding strategies have been used to improve this, as well as using condensing
agents such as histones that also possess nuclear localisation properties [210], but generally,
NLSs are used to supplement other delivery systems rather than as stand-alone vectors.
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6.7. Designer Biomimetic Vectors (DBVs)
An exciting approach to the multifunctional vector has been the introduction of recombinant
production of bio-inspired fused protein sequences, each coding for a discrete motif with an
explicit barrier evasion function [211]. Termed designer biomimetic vectors, these vectors are
rationally designed to incorporate several motifs with distinct functions, and could be a step
towards the production of ‘artificial viruses’. The previous strategies discussed involving
different components of a multi-functional system being conjugated together by various
attachments may not be ideal for production of gene delivery systems. Simple conjugation of
certain peptides has also led to alteration in the function of the peptides [212], therefore
conjugating all the desired components together may be problematic. Production of DBVs
using recombinant DNA technology allows the fusion of discrete motifs in a relatively simple
process that should not affect the functional operation of the motifs. This would circumvent
any problems involved with complex conjugation reactions to attach different components
and ultimately could be more cost effective and reproducible in a large scale industrial setting.
The production process involves introduction of plasmids, which have been engineered to
contain the desired motifs for the protein, into competent bacterial cells. The bacteria then
utilise the plasmid to produce the fusion proteins, which are subsequently extracted and
purified. The use of this recombinant DNA technology allows the specific design of the vector
at the molecular level, which can be tailored to enhance and optimise gene delivery [213].
Examples of multi-functional recombinant vectors are detailed in Table 2.
Name Nucleic acid
condensation
Endosomolytic
component
Nuclear
localisation
Targeting
motif
Other Activity
Tetra-
H2A(TH)
Four tandem
repeats of human
histone H2A
peptide (TH)
GALA peptide N/A (anti-
luciferase
siRNA
delivery)
Anisamide
(AA) to
target cancer
cells that
overexpress
sigma
receptor
PEGylated,
cathepsin D
cleavage sites in
the TH for
digestion in
endosome
compartment,
DOTAP and
Chol Lipid
envelope
surrounding
TH
TH produced a higher
silencing efficiency in
HT60-luc cells in vitro
and in vivo than the
NPs assembled with
protamine as the
nucleic acid
condensing agent [218].
KALA-2H1-
NLS-TP
Two repeating
units of histone
H1 (2H1)
KALA peptide NLS from Rev
protein of HIV
virus
ZR-75-1
targeting
peptide
(RVCFLWQ
DGRCVF)
- Transfection efficiency
of luciferase
comparable to PEI 25
kDa with preferential
targeting to ZR-75-1
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Name Nucleic acid
condensation
Endosomolytic
component
Nuclear
localisation
Targeting
motif
Other Activity
breast cancer cells
[186].
FP–(DCE)n–
NLS–CS–TM
FP– (DCE)n–
CS–TM
Arginine-
histidine (RH)
with general
structure
(RRXRRXHHXH
HX)n
Arginine-
histidine (RH)
M9 (included
in FP–(DCE)n–
NLS–CS–TM
for DNA
delivery;
absent in FP–
(DCE)n–CS–
TM for siRNA
delivery)
HER2
targeting
affibody to
target
SKOV-3
- Significant cell death
observed in SKOV-3
cells treated in vitro
with FDT/BCL2-siRNA
in combination with
FDNT/pSR39 plus GCV
[216,217].
DBV µ peptide derived
from adenovirus
H5WYG Rev HER2
affibody
Targeting
moiety attached
via cathepsin
substrate (CS)
for cleavage in
the endosome
DBV-mediated iNOS
gene delivery resulted
in a maximum of 62%
cell killing and less
than 20% clonogenicity
in ZR-75-1 breast
cancer cells in vitro
[215].
Table 2. Recombinant multifunctional non-viral delivery systems, their components, and application in gene therapy
Recently the Gandehari and Hatefi groups have reported the design and development of
recombinant fusion proteins for targeted gene delivery [34, 211]. The DBVs are produced by
fusing the desired motif sequences, usually composed of a DNA condensing motif (DCM),
endosomal disruption motif (EDM) and nuclear localisation motif (NLS) [34, 214]. Sadeghian
et al. described a fusion protein comprised of two repeats of histone H1 for DNA condensation,
H5WYG pH responsive fusogenic peptide for endosomal escape and the simian virus 40 (SV40)
large T-antigen NLS for a nuclear localization [211]. The fusion peptide was complexed with
the pGL3 plasmid for luciferase expression to form nanoparticles; the nanoparticles transfected
Chinese hamster ovary (CHO) cells efficiently in vitro. However, this system lacked a targeting
motif that is highly desirable in the design of gene delivery system.
Soltani et al. recently described a delivery system known as KALA-2H1-NLS-TP, which is
composed of two repeating units of histone H1 (2H1) to efficiently condense DNA into nano-
sized particles, a synthetic pH-dependent endosome disrupting motif (KALA) to promote
escape from endosomes, a cyclic targeting peptide (TP) selected from a phage display library
to target antigens on the surface of ZR-75-1 breast cancer cells, and an NLS from the Rev protein
of HIV to facilitate translocation of DNA towards the cell nucleus [186]. The authors demon‐
strated that the recombinant vector had a high rate of gene transfection efficiency compared
to vectors that lacked one or more functional motifs, and targeted the ZR-75-1 cells. Besides
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the ability to target, the developed multifunctional vector was able to disrupt endosomal
membranes, reach the nucleus by utilizing microtubules, and transfect efficiently while
showing no detectable toxicity. McCarthy et al. presented similar results using a DBV for the
delivery of iNOS gene therapy targeted to breast cancer [215].
Canine et al. described a biopolymer termed FP–(DCE)n–NLS–CS–TM that contains repeating
units of arginine and histidine to condense pDNA and lyse endosome membranes (DCE), a
HER-2 targeting affibody to target cancer cells (TM), a pH responsive fusogenic peptide (FP)
H5WYG to destabilize endosome membranes and enhance endosomolytic activity of histidine
residues, and a nuclear localization signal (NLS) M9 to enhance translocation of pDNA
towards the cell nucleus. A cathepsin D enzyme substrate (CS) was also engineered in between
targeting motif and NLS to facilitate dissociation of the targeting motif from the biopolymer
inside late endosomes where cathepsin D is abundant [216]. The authors demonstrated the
functioning of each motif in the polymer resulting in successful transfection of SKOV-3 and
GFP transgene expression.
The production of these recombinant vectors renders it relatively easy to change their charac‐
teristics by sequence modification. Canine et al. further demonstrated that by modifying the
sequence of the biopolymer FP–(DCE)n–NLS–CS–TM, it was possible to fine tune the vector
for either delivery of plasmid DNA to the nucleus or delivery of siRNA to the cytoplasm [217].
It was reported that inclusion of the M9 NLS rendered the biopolymer (FP–(DCE)n–NLS–CS–
TM) suitable for delivery of plasmid DNA to the nucleus but not for delivery of siRNA.
However, exclusion of the NLS from the biopolymer (FP– (DCE)n–CS–TM) rendered it more
suitable for delivery of siRNA to the cytoplasm but not for nuclear delivery of plasmid DNA
in SKOV-3 human ovarian cancer cells. This study demonstrates the possibility of not only
targeting specific cells for gene delivery, but also the ability to target intracellular compart‐
ments depending on the nature of the therapeutic to be delivered.
Wang et al. presented a novel recombinant protein tetra-H2A (TH) derived from histone H2A
that was developed to replace protamine as a conditionally reversible, nucleic acid condensing
agent. The recombinant protein comprised of four tandem repeats of human histone H2A
peptide, interspersed with cathepsin D cleavage sites and a pH-responsive fusogenic peptide
GALA to facilitate the endosome escape of the cargo. The recombinant protein, tetra-H2A (TH),
was able to condense siRNA into a stable complex that was in turn coated in a cationic lipid
with a high degree of PEGylation, forming Lipid-tetra-H2A-Hyaluronic acid (LHH) nanopar‐
ticles [218]. This design was developed in order to mimic lipid-enveloped viruses to replicate
the transfection abilities of viruses in vivo. The histone-containing polymer demonstrated an
enhanced intracellular release of the cargo and an increased anti-luciferase siRNA silencing
efficiency in vitro compared with the protamine-containing polymer in H460-luc human lung
carcinoma cells. Furthermore, in vivo gene silencing by tumour-targeted anti-luciferase siRNA
was evaluated in H460-luc xenograft-bearing mice with the histone-containing nanoparticles
loaded with anti-luciferase siRNA resulting in ~66% silencing of luciferase expression,
significantly higher than that of the protamine-mediated knockdown (34%). This study
demonstrates the importance of efficient release of the genetic payload for efficient gene
therapy; through optimisation of each component of the multifunctional vector, it may be
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possible to maximise transfection efficiency. However, these vectors are still in the early stage
of development and much research is needed. Many of these findings serve only to confirm
the theory behind the design of the vector, and further in vivo work with therapeutic trans‐
genes is ultimately required.
7. Conclusion
There is a huge potential for cancer gene therapy, which, in some respect, has yet to be realised.
However, the lack of gene therapy products making it onto the market is disappointing when
one considers the number of research groups involved and clinical trials underway. It seems
that until a suitable delivery system for cancer gene therapy becomes available, the potential
of this field will never be reached. The difficulty in this is the number of hurdles to overcome
and the extremely high standards of safety and efficiency expected by regulatory authorities.
Nevertheless, the development of multifunctional systems and a move towards the creation
of artificial viruses may finally help cancer gene therapy to progress to a viable and successful
cancer treatment.
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